PATENT APPLICATION ATTORNEY DOCKET NO. T8341.NP.CON

THE UNITED STATES PATENT & TRADEMARKS OFFICE

ART UNIT:

1617

EXAMINER:

UNKNOWN

APPLICANT:

Xiong et al.

SERIAL NO.:

10/723,435

FILED:

11/26/2003

CONFRM. NO.: 6215

FOR: TRANSDERMAL ADMINISTRATION OF

HUPERZINE

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

DATE OF DEPOSIT: 08/26/04

I hereby certify that this paper or fee (along with any paper or fee referred to as being attached or enclosed) is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated above and is addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450. Alexandria, VA 22312-1450.

Denise Dver

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir/Madam:

Please find, pursuant to 37 C.F.R. § 1.98(a)(1), the enclosed Form PTO-1449 which contains a list of all patents, publications, or other items that have come to the attention of one or more of the individuals designated in 37 C.F.R. § 1.56(c). Applicant respectfully submits that this Information Disclosure Statement is filed pursuant to:

37 C.F.R. § 1.97 (b)(1) or (3), within three months of the filing date of the application, or before a first office action on the merits, whichever occurs last;

37 C.F.R. § 1.97 (c), after a first office action on the merits, but before a Final Office Action or a Notice of Allowance, whichever occurs first, and is accompanied by either 1) a statement in accordance with 37 C.F.R. § 1.97(e), or 2) the fee set forth in§1.17(p); or

37 C.F.R. § 1.97 (d), after a Final Office Action or Notice of Allowance, whichever occurs first, but on or before payment of the issue fee, and is accompanied by both 1) a statement in accordance with 37 C.F.R. § 1.97(e), and 2) the fee set forth in§1.17(p).

While no representation is made that any of these references may be "prior art" within the meaning of that term in accordance with 35 U.S.C. §§ 102 or 103, the enclosed list of references is disclosed so as to comply with the duty of disclosure set forth in 37 C.F.R. § 1.56.

Moreover, while no representation is made that a specific search of office files or patent office records has been conducted or that no better art exists, the undersigned attorney of record believes that the references listed, together with any other references which may have been previously submitted or listed, are the closest to the claimed invention (taken in its entirety) of which the undersigned is presently

. \

Supplemental Information Disclosure Statement Application No. <u>10/723,435</u> Page 2

aware, and no art which is closer to the claimed invention (taken in its entirety) has been knowingl
withheld.
A legible copy of each listed U.S. Patent or publication (or relevant portion thereof
which was not previously submitted to, or cited by, the Patent Office is enclosed pursuant to 3
C.F.R. §§ 1.97 and 1.98.
A legible copy of each of the listed non-patent literature and foreign documents of
their relevant portions is enclosed.
Copies of cited U.S. patents and/or publications are NOT enclosed pursuant to th
Official Gazette Notice, dated Aug. 5, 2003, waiving the requirement of 37 C.F.R. § 1.98(a)(2)(i).
Copies of the references listed in the accompanying Form PTO-1449 are NOT enclose
because, under 37 C.F.R. § 1.98(d), they were previously cited by or submitted to the Office i
application number, which is relied upon for an earlier filing date under 35 U.S.C.
120.
For all listed references that are not either in the English language, or accompanied by
translation into English, a concise explanation of relevance as required under 37 C.F.R. § 1.98(a)(3)

translation into English, a concise explanation of relevance as required under 37 C.F.R. § 1.98(a)(3) is enclosed attached to each.

The Commissioner is hereby authorized to charge any additional fees associated with this communication or to credit any overpayment to Deposit Account No. 20-0100.

Dated this 26 day of August, 2004.

Respectfully submitted,

M. Wayne Western Attorney for Applicant

Registration No. 22,788

THORPE NORTH & WESTERN, LLP Customer No. 20,551 P.O. Box 1219 Sandy, Utah 84091-1219

Telephone: (801) 566-6633

MWW/DWO/dd Enclosure





M. Wayne Western Registered Patent Attorney western@tnw.com

David W. Osborne Registered Patent Attorney osborne@tnw.com

August 25, 2004

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Re:

U.S. Patent Application No. 10/723,435 filed 11/26/2003

Applicant: Xiong, et al.

Title: TRANSDERMAL ADMINISTRATION OF HUPERZINE

Group Art Unit: 1617

Attorney Docket No. T8341.NP.CON

Sir/Madam:

Transmitted herewith for filing and pursuant to 37 C.F.R. §§ 1.56 and 1.97 is a Supplemental Information Disclosure Statement. Enclosed also are the following designated documents, as required under 37 C.F.R. §§ 1.97 and 1.98:

\boxtimes	Form PTO-1449 list of 15 references submitted for consideration.
	Legible copies of the listed references or their relevant portions.
\boxtimes	Legible copies of the listed <u>non-patent documents and foreign documents</u> or their relevant portions are included.
\boxtimes	Copies of U.S. patents and/or publications are not included pursuant to the Official Gazette Notice, dated Aug. 5, 2003, waiving the requirement of 37 C.F.R. 1.98(a)(2)(i).
	All English translations of each non-English reference, if any, within the possession, custody, control or availability of anyone designated in 37 C.F.R. § 1.56(c) (see 37 C.F.R. § 1.98(c)).

The following are included within the Information Disclosure Statement if applicable and as required under 37 C.F.R. § 1.98: \boxtimes Concise explanation of relevance of each reference not in English and unaccompanied by an English translation. Statement that certain listed references not enclosed are substantially cumulative of an enclosed reference. Statement that certain listed references not enclosed were previously cited by or submitted to the Office in prior application no. , filed on _____, which is relied upon for an earlier filing date under 35 U.S.C. § 120. In order to secure consideration of the items designated above, one or more of the following, if required, is also enclosed: Statement under 37 C.F.R. § 1.97(e)(1) or (2). 冈 Check No. _____, which includes the amount of \$0.00 (amount in \$1.17(p)) constituting the submission fee set forth in 37 C.F.R. § 1.17(p).

In the event that 37 C.F.R. § 1.97(c) applies and the Examiner is not satisfied that the Statement meets the requirements of 37 C.F.R. § 1.97(e), or in any other event remediable by a fee, please credit any over payment or charge any additional fees to Deposit Account No. 20-0100 of the undersigned.

Respectfully submitted,

m, Waym Weate

M. Wayne Western

Attorney for Applicant Registration No. 22,788

THORPE NORTH & WESTERN, LLP

Customer No. 20,551

P.O. Box 1219

Sandy, Utah 84091-1219

Telephone: (801) 566-6633

WWW/DWO/99



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO. T8341.NP.CON

SERIAL NO. 10/723,435

LIST OF PRIOR ART CITED BY APPLICANT

APPLICANT Xiong et al.

FILING DATE 11/26/2003

GROUP 1615

U.S. PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	Al	US 4,849,224	07/18/1989	Chang et al.			
	A2	US 4,983,395	01/08/1991	Chang et al.			
	A3	US 5,122,383	06/16/1992	Heiber et al.			
	A4	US 5,359,087	10/25/1994	Johnson et al.			
,,,	A5	US 5,460,820	10/24/1995	Ebert et al.			
	A6	US 5,656,286	09/12/1997	Miranda et al.			
	A7	US 5,663,344	09/02/1997	Kozikowski et al.			
	A8	US 5,762,953	06/09/1998	Venkateshwaran			
	A9	US 6,019,988	02/2000	Parab et al.			
	A10	US 6,024,976	02/15/2000	Miranda et al.		·	
	All	US 6,159,986	12/2000	Altman, David A.			
	A12	US 6,352,715	03/2002	Hwang et al.			

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
A13 CN 11/1995		China (name: Zhejiang ACAD Mediacl SCI)					

OTHER PRIOR ART (Including Author, Title, Pertinent Pages, Etc.)

	A14	Klingman and Christopher (Arch. Dermatol. 88:702 (1963)						
EXAMINER			DATE CONSIDERED					

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication with applicant.